Jiraporn Puangkaew

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The RV144 prime-boost regimen demonstrated efficacy against HIV acquisition while VAX003 and VAX004 did not. Although these trials differed by risk groups, immunization regimens, and immunogens, antibody responses may have contributed to the differences observed in vaccine efficacy. We assessed HIV-specific IgG, both total and subclass, and IgA binding to(More)
  • 1